EGFR (D770_N771insG)
Sign in to save this workspaceEGFR · Variant type: indel · HGVS: p.D770_N771insG
Drug response on this variant
| # | Drug | Inhibition on variant | Residual | KISS |
|---|---|---|---|---|
| 1 | Mobocertinib | 100.0% | 0.0% | 97.22 |
| 2 | Canertinib | 100.0% | 0.0% | 96.49 |
| 3 | Lazertinib | 99.5% | 0.5% | 97.47 |
| 4 | Neratinib | 98.3% | 1.7% | 93.18 |
| 5 | Pralsetinib | 97.8% | 2.2% | 93.43 |
| 6 | Erlotinib | 96.6% | 3.4% | 99.75 |
| 7 | Vandetanib | 95.7% | 4.3% | 95.74 |
| 8 | Alpelisib | 91.0% | 9.0% | 97.22 |
| 9 | Pacritinib | 84.0% | 16.0% | 88.64 |
| 10 | Gilteritinib | 59.2% | 40.8% | 88.97 |
| 11 | Pemigatinib | 54.5% | 45.5% | 98.23 |
| 12 | Zanubrutinib | 52.3% | 47.7% | 98.24 |
| 13 | Pexidartinib | 28.1% | 71.9% | 99.49 |
| 14 | Defactinib | 26.9% | 73.1% | 92.68 |
| 15 | Fedratinib | 26.3% | 73.7% | 96.21 |
| 16 | Pirtobrutinib | 23.3% | 76.7% | 99.49 |
| 17 | Avapritinib | 21.3% | 78.7% | 97.73 |
| 18 | Entrectinib | 17.7% | 82.3% | 93.69 |
| 19 | Rabusertib | 13.9% | 86.1% | 98.74 |
| 20 | Abrocitinib | 12.2% | 87.8% | 99.50 |
| 21 | Repotrectinib | 10.8% | 89.2% | 84.21 |
| 22 | Tenalisib | 8.3% | 91.8% | 97.98 |
| 23 | Idelalisib | 7.7% | 92.3% | 100.00 |
| 24 | Darovasertib | 7.5% | 92.5% | 96.99 |
| 25 | Abemaciclib | 7.4% | 92.6% | 91.48 |
Wild-type vs variant — drug response delta
Positive Δ means the drug hits the variant harder than wild-type (mutation-selective); negative Δ means it loses potency (resistance).
| Drug | Variant inh | WT inh | Δ (variant − WT) |
|---|---|---|---|
| Mobocertinib | 100.0% | 100.0% | +0.0% |
| Canertinib | 100.0% | 98.4% | +1.6% |
| Lazertinib | 99.5% | 100.0% | -0.5% |
| Neratinib | 98.3% | 100.0% | -1.7% |
| Pralsetinib | 97.8% | 99.1% | -1.4% |
| Erlotinib | 96.6% | 99.4% | -2.8% |
| Vandetanib | 95.7% | 99.3% | -3.7% |
| Alpelisib | 91.0% | — | — |
| Pacritinib | 84.0% | — | — |
| Gilteritinib | 59.2% | 91.0% | -31.9% |
| Pemigatinib | 54.5% | — | — |
| Zanubrutinib | 52.3% | 88.2% | -35.9% |
| Pexidartinib | 28.1% | — | — |
| Defactinib | 26.9% | 94.6% | -67.7% |
| Fedratinib | 26.3% | — | — |
| Pirtobrutinib | 23.3% | — | — |
| Avapritinib | 21.3% | — | — |
| Entrectinib | 17.7% | — | — |
| Rabusertib | 13.9% | — | — |
| Abrocitinib | 12.2% | — | — |
| Repotrectinib | 10.8% | — | — |
| Tenalisib | 8.3% | — | — |
| Idelalisib | 7.7% | — | — |
| Darovasertib | 7.5% | — | — |
| Abemaciclib | 7.4% | — | — |
Annotations
Sign in to read and post annotations.
Loading…
Served from saifudeen2026@1.0.0 · API 0.1.0 · 14.2ms